§
Luxuse
Patent Intelligence
Sign In
Patent US5855610A successfully refreshed from Google Patents.
← Back to Patent Explorer
US5855610A Expired / Lapsed US ⏱️ 0.0 years remaining

Engineering of strong, pliable tissues

Assignee: Boston Children's Hospital
•
Filing: 1995-05-19
•
Granted: 1999-01-05
•
Expires: 2015-05-19
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract It has been discovered that improved yields of engineered tissue following implantation, and engineered tissue having enhanced mechanical strength and flexibility or pliability, can be obtained by implantation, preferably subcutaneously, of a fibrous polymeric matrix for a period of time sufficient to obtain ingrowth of fibrous tissue and/or blood vessels, which is the removed for subsequent implantation at the site where the implant is desired. The matrix is optionally seeded prior to the first implantation, after ingrowth of the fibrous tissue, or at the time of reimplantation. The time required for fibrous ingrowth typically ranges from days to weeks. The method is particularly useful in making valves and tubular structures, especially heart valves and blood vessels.

Inventors

  • 👤 Joseph P. Vacanti
  • 👤 Christopher K. Breuer
  • 👤 Beverly E. Chaignaud
  • 👤 Toshiraru Shin'oka

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 15:24
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/36; A61L27/38; A61L27/3886; A61L27/14; A61L27/18; A61L27/3604; A61L27/3633; A61L27/3641; A61L27/3645; A61L27/3804; A61L27/3839; A61L27/3843; A61L27/50; A61L27/507; A61F; A61F2/00; A61F2/02; A61F2/24; A61F2/2412; A61F2/2415

Claims Analysis

Total Claims: 11
Claim 1
Independent Claim 74 words
A cell-matrix structure comprising a fibrous matrix formed of a biocompatible, biodegradable synthetic polymer, and seeded with dissociated human cells, wherein the matrix is configured to form a tissue structure having mechanical strength and flexibility or pliability, wherein the cell-matrix structure is formed by seeding the matrix, implanting the seeded matrix into a recipient human or animal for a period of time sufficient to form extracellular matrix; and harvesting of the resulting cell-matrix structure.
Claim 2
Dependent Claim 74 words
A cell-matrix structure comprising a fibrous matrix formed of a biocompatible, biodegradable synthetic polymer, and seeded with dissociated human cells, wherein the matrix is configured to form a tissue structure having mechanical strength and flexibility or pliability, wherein the cell-matrix structure is formed by seeding the matrix, implanting the seeded matrix into a recipient human or animal for a period of time sufficient to form extracellular matrix; and harvesting of the resulting cell-matrix structure.
Claim 3
Dependent Claim 15 words
The cell-matrix structure of claim 1 wherein the matrix is configured to form a tube.
Claim 4
Dependent Claim 22 words
The cell-matrix structure of claim 1 wherein the matrix is configured to form a valve in a blood vessel, intestine, or heart.
Claim 5
Dependent Claim 16 words
The cell-matrix structure of claim 3 wherein the matrix is configured to form a heart valve.
Claim 6
Dependent Claim 22 words
The cell-matrix structure of claim 1 wherein the cells are selected from the group of consisting of parenchymal and connective tissue cells.
Claim 7
Dependent Claim 43 words
A tissue-engineered heart valve formed of a porous polymeric matrix seeded with dissociated endothelial and fibroblast cells, wherein the cells form extracellular matrix following implantation into a human or animal recipient, and wherein the extracellular matrix is shaped to form a heart valve.
Claim 8
Dependent Claim 43 words
A tissue-engineered heart valve formed of a porous polymeric matrix seeded with dissociated endothelial and fibroblast cells, wherein the cells form extracellular matrix following implantation into a human or animal recipient, and wherein the extracellular matrix is shaped to form a heart valve.
Claim 9
Dependent Claim 27 words
The heart valve of claim 6 wherein the matrix is formed of a polymer selected from the group consisting of poly(lactic acid), poly(glycolic acid), and combinations thereof.
Claim 10
Dependent Claim 42 words
The heart valve of claim 7 wherein the matrix is formed of polymer fibers having an interstitial spacing of between 100 and 300 microns and having pore sizes and structure to control the pattern and extent of fibroblastic tissue ingrowth following implantation.
Claim 11
Dependent Claim 29 words
The heart valve of claim 7 wherein the matrix was seeded with dissociated cells selected from the group consisting of fibroblasts, myofibroblasts, and endothelial cells and includes elastin fibers.

References Cited (Backward Citations)

US1995970A Cited
US2609347A Cited
US2664366A Cited
US2653917A Cited
US2676945A Cited
US2683136A Cited
US2703316A Cited
US2659936A Cited
US2758987A Cited
US2846407A Cited
US2951828A Cited
US3531551A Cited
US4239684A Cited
US3880991A Cited
US4069307A Cited
US3935065A Cited
US3960150A Cited
US4026304A Cited
US3883393A Cited
US3826241A Cited
US4450150A Cited
US3974526A Cited
US3996444A Cited
US3902497A Cited
US4192827A Cited
US3992726A Cited
US3949073A Cited
US4144126A Cited
US4280954A Cited
US4060081A Cited
US4186448A Cited
US4391797A Cited
US4141087A Cited
US4328204A Cited
US4205399A Cited
US4137921A Cited
US4304591A Cited
DE2853614A1 Cited
US4228243A Cited
US4277682A Cited
US4243775A Cited
US4456687A Cited
US4713070A Cited
US4352883A Cited
US4304866A Cited
US4444887A Cited
US4348329A Cited
US4356261A Cited
US4347847A Cited
US4563490A Cited
US4427808A Cited
US4576608A Cited
US4675189A Cited
US4416986A Cited
US4553272A Cited
US4431428A Cited
US4438198A Cited
US4446234A Cited
US4458678A Cited
US4505266A Cited
US4485096A Cited
US4439152A Cited
US4494386A Cited
US4545082A Cited
US4520821A Cited
US4544518A Cited
US4528265A Cited
US4485097A Cited
US4495174A Cited
US4440921A Cited
US4489056A Cited
US4559304A Cited
US4645669A Cited
US4559298A Cited
US4446229A Cited
US4642120A Cited
DE3318150C2 Cited
US4689293A Cited
US4563489A Cited
EP0153895B1 Cited
US4609551A Cited
US4886870A Cited
US4888176A Cited
US4891225A Cited
US4778749A Cited
US4675284A Cited
US4757017A Cited
US4637931A Cited
US4563350A Cited
US4595713A Cited
US4868121A Cited
US4627853A Cited
US4681763A Cited
US4853324A Cited
EP0226061B1 Cited
US4721096A Cited
US4880622A Cited
EP0248248B1 Cited
EP0248247B1 Cited
US4734373A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 2002-01-04 2002-07-06 2003-01-05 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2006-01-04 2006-07-06 2007-01-05 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2010-01-04 2010-07-06 2011-01-05 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag